XIENCE: The New Direction in Left Main Stenting

In the past, patients with obstructive left main coronary artery disease (LMCAD) have usually been treated with coronary artery bypass grafting (CABG). These patients' high morbidity and mortality are due to the large amount of myocardium at risk. Now the EXCEL trial1 shows that, using XIENCE, percutaneous coronary intervention (PCI) is a suitable, and less invasive, option in patients with a SYNTAX score < 32.

XIENCE Sierra is uniquely designed to post dilate to 5.5 mm.#

Review Latest Data for Left Main Disease

The EXCEL trial demonstrates the safety of XIENCE revascularization for patients with left main disease who have a SYNTAX score of 32 or lower.  

“A major difference between PCI and CABG was the 30-day incidence of procedural myocardial infarction (MI). Large MIs, including ST-segment elevation MIs, were substantially more common with bypass surgery than with PCI. In part that's because graft failure, early on, was more common with bypass surgery than with PCI.”

— Gregg Stone, MD, at TCT referring to EXCEL trial

Experts' Point of View: Applying EXCEL Results to Clinical Practice

“It was a fairly complex [patient population]: 80% bifurcation, 25-30% heavily calcified. And at 3-year follow-up we had a 0.7% incidence of definite stent thrombosis.”

Gregg Stone, MD, interviewed by C. Michael Gibson, MD

Play video

XIENCE Demonstrates Extremely Low Definite Stent Thrombosis Rates

Because of recent improvements in PCI and surgical outcomes, and use of the SYNTAX scoring tool, the EXCEL trial was designed to re-examine safety in left main stenting. EXCEL randomized 1,905 patients with unprotected left main disease—and low or intermediate anatomical complexity, e.g., a SYNTAX score of 32 or lower— either to CABG or to PCI with XIENCE.1

The EXCEL trial results showed a significant difference in definite stent thrombosis or symptomatic graft occlusion.

XIENCE vs CABG: 87% Lower Rate of Definite ST or Symptomatic Graft Occlusion at 3 Years

XIENCE Non-Inferiority: Preferred or Acceptable* to CABG in Selected Left Main Patients 

XIENCE Non-Inferiority: Preferred or Acceptable* to CABG in Selected Left Main Patients

The 2 arms of the EXCEL trial showed no significant differences in the primary endpoint (death, stroke and MI) at 3 years. Most of the patients (80.5%) had distal left main bifurcation or trifurcation disease.1

Primary Endpoint at 3 Years: Death, MI, Stroke (Intention to Treat) 

XIENCE Non-Inferiority: Preferred or Acceptable* to CABG in Selected Left Main Patients 


EXCEL revealed that PCI using everolimus-eluting stents (EES) was non-inferior to CABG. The authors concluded that PCI with EES is an acceptable or perhaps preferred* alternative to CABG in selected LMCAD patients. 

Authors' analysis of the screening registry suggests that about 62% of LMCAD patients might be eligible for PCI.*

Note: Placement of the stent in the left main coronary artery has the potential to compromise blood flow to the distal anatomy.

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

# Maximum expansion for 3.5 mm and 4.0 mm

* The CABG vs PCI treatment decision should be made after heart team discussion, taking into account each patient’s circumstances and preferences.

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Stone, G. First Presentation of the EXCEL 4-Year Outcomes. TCT 2018 Presentation.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?


The website you have requested is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit this website?